Nucleoside transporter proteins.

@article{MolinaArcas2009NucleosideTP,
  title={Nucleoside transporter proteins.},
  author={Miriam Molina-Arcas and Francisco Javier Casado and Marçal Pastor-Anglada},
  journal={Current vascular pharmacology},
  year={2009},
  volume={7 4},
  pages={
          426-34
        }
}
Concentrative nucleoside transporters (CNT; SLC28) and equilibrative nucleoside transporters (ENT; SLC29) mediate the uptake of natural nucleosides and a variety of nucleoside-derived drugs, mostly used in anticancer therapy. SLC28 and SLC29 families consist in three and four members, respectively, which differ in their substrate selectivity and their energy requirements. Tissue distribution of these transporters is not homogeneous among tissues, and their expression can be regulated. In… Expand
The SLC28 (CNT) and SLC29 (ENT) nucleoside transporter families: a 30-year collaborative odyssey.
  • James D Young
  • Biology, Medicine
  • Biochemical Society transactions
  • 2016
TLDR
This mini-review describes a 30-year collaboration with Professor Stephen Baldwin to identify and understand the structures and functions of these physiologically and clinically important transport proteins. Expand
Current Progress on Equilibrative Nucleoside Transporter Function and Inhibitor Design
TLDR
An overview of the known structure–function relationships of the ENT family is provided with a focus on ligand binding and transport in the context of a new hENT1 homology model and a generic residue numbering system is provided to facilitate the interpretation of mutational data produced using different ENT homologs. Expand
Equilibrative Nucleoside Transporter 2: Properties and Physiological Roles
TLDR
The main roles of ENT2 are highlighted and a brief update on the recent research is provided, aimed at highlighting the main roles in signaling pathway and cell cycle progression. Expand
Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters
TLDR
A combination of X-ray crystallographic and equilibrium-binding studies probing the molecular origins of nucleosides and nucleoside drug selectivity of a CNT from Vibrio cholerae are presented and chemically modifying an anticancer drug so that it is better transported by and selective for a single human CNT subtype. Expand
Emerging Roles of Nucleoside Transporters
TLDR
HENTs and hCNTs have a crucial role in salvage pathways and purinergic signaling by means of nucleoside pools regulation, and the two new hENT2 isoforms recently described seem to be key elements controlling nucleosid and nucleotide pools for DNA synthesis. Expand
Crystal structure of a concentrative nucleoside transporter from Vibrio cholerae at 2.4 Å
TLDR
The crystal structure of a concentrative nucleoside transporter from Vibrio cholerae in complex with uridine is presented, and functional data show that, like its human orthologues, the transporter uses a sodium-ion gradient for nucleosides transport. Expand
Equilibrative nucleoside transporters—A review
TLDR
Findings on the characterization of ENTs are highlighted by surveying studies on genetics, permeant and inhibitor interactions, mutagenesis, and structural models of ENT function. Expand
Nucleoside Reverse Transcriptase Inhibitor Interaction with Human Equilibrative Nucleoside Transporters 1 and 2
TLDR
An in vitro model using S-[(4-nitrophenyl)methyl]-6-thioinosine to differentiate between equilibrative nucleoside transporter (ENT) 1- and ENT2-mediated uridine transport in HeLa cells shows that HeLa S3 cells can be used to explore complex transporter selectivity and are an adequate model for studying ENTs present at the BTB. Expand
Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets
TLDR
A state-of-the-art overview of the clinical evidence generated so far supporting the concept that nucleoside and nucleobase proteins can indeed be biomarkers suitable for diagnosis and/or prognosis is provided. Expand
Equilibrative Nucleoside Transporter 1 (ENT1, SLC29A1) Facilitates Transfer of the Antiretroviral Drug Abacavir across the Placenta
TLDR
Drug-drug interactions and the effect of interindividual variability in placental ENT1 expression on abacavir disposition into fetal circulation should be further investigated to guarantee safe and effective abacvir-based combination therapies in pregnancy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 142 REFERENCES
The concentrative nucleoside transporter family, SLC28
TLDR
Nucleoside transporters in the SLC28 and SLC29 families play critical roles in nucleoside salvage pathways where they mediate the first step of nucleotide biosynthesis and work in concert to terminate adenosine signaling. Expand
Nucleoside transporter proteins: emerging targets for drug discovery
TLDR
This review focuses on the nucleoside transporter proteins of humans and rodents that have become known through molecular cloning and functional expression of their cDNAs, and describes relationships with the transporters of lower organisms. Expand
Cell entry and export of nucleoside analogues.
TLDR
This review focuses on the transporter-mediated pathways implicated in either the uptake or the efflux of nucleoside- and nucleobase-derivatives, and the basic properties of these carrier proteins and their respective role in the transport across the plasma membrane of nucleo-derived antiviral drugs are reviewed. Expand
The equilibrative nucleoside transporter family, SLC29
TLDR
The human SLC29 family of proteins contains four members, designated equilibrative nucleoside transporters (ENTs) because of the properties of the first-characterised family member, hENT1, which possess similar broad substrate specificities for purine and pyrimidine nucleosides, but hENT2 in addition efficiently transports nucleobases. Expand
Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney.
TLDR
The role that nucleosid transporters play in renal disposition of nucleosides and nucleoside analogs in both systemic and kidney-specific therapies is examined. Expand
Nucleoside transporters: from scavengers to novel therapeutic targets.
TLDR
Recent research indicates novel putative functions for CNS nucleoside transporters in sleep, arousal, drug and alcohol addiction, nociception and analgesia, and the therapeutic use of nucleosides analogue drugs and nucleosid transporter inhibitors in viral, neoplastic, cardiovascular and infectious disease is described. Expand
Nutritional regulation of nucleoside transporter expression in rat small intestine.
TLDR
Substrate availability modulates nucleoside transporter expression (CNT1) in rat jejunum in vivo and, accordingly, jejunal brush border membrane vesicles from 48-hour-fasted rats showed increased expression of CNT1 and enhanced Na(+)-dependent thymidine and gemcitabine uptake. Expand
Molecular requirements of the human nucleoside transporters hCNT1, hCNT2, and hENT1.
TLDR
These models reveal that hCNT2 affinity is dominated by hydrogen bonding features, whereas hC NT1 and hENT1 displayed mainly electrostatic and steric features, which should assist the design of high-affinity nucleoside transporter inhibitors and substrates for both anticancer and antiviral therapy. Expand
Cloning of a human nucleoside transporter implicated in the Cellular uptake of adenosine and chemotherapeutic drugs
TLDR
The isolation of a human placental cDNA encoding a 456-residue glycoprotein with functional characteristics typical of an es-type transporter is reported, predicted to possess 11 membrane-spanning regions and is homologous to several proteins of unknown function in yeast, nematodes, plants and mammals. Expand
Physiological Roles of Vascular Nucleoside Transporters
TLDR
Vascular NTs are critical in modulating adenosine-mediated responses during conditions such as inflammation or hypoxia, which among others plays an important role in tissue protection during acute injury. Expand
...
1
2
3
4
5
...